@prefix dcterms: <http://purl.org/dc/terms/> .
@prefix ns1: <http://www.w3.org/ns/prov#> .
@prefix this: <http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA> .
@prefix sub: <http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_3908> bl:category bl:Disease .
  
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_3908>;
    rdf:predicate bl:treats;
    rdf:subject <https://identifiers.org/drugbank:DB09035>;
    a rdf:Statement;
    rdfs:label "opdivo is a programmed death receptor 1 pd 1 blocking antibody indicated for the treatment of 1 1 1 2 1 3 a 1 4 1 5 1 5 a 1 6 1 7 a 1 8 a 1 9 a 1 1 a opdivo as a single agent or in combination with ipilimumab is indicated for the treatment of patients with unresectable or metastatic melanoma opdivo is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection opdivo is indicated for the treatment of patients with metastatic non small cell lung cancer nsclc with progression on or after platinum based chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on fda approved therapy for these aberrations prior to receiving opdivo opdivo is indicated for the treatment of patients with metastatic small cell lung cancer sclc with progression after platinum based chemotherapy and at least one other line of therapy this indication is approved under accelerated approval based on overall response rate and duration of response see clinical studies 14 4 opdivo in combination with ipilimumab is indicated for the treatment of patients with intermediate or poor risk previously untreated advanced rcc opdivo is indicated for the treatment of adult patients with classical hodgkin lymphoma chl that has relapsed or progressed after autologous hematopoietic stem cell transplantation hsct and brentuximab vedotin or 3 or more lines of systemic therapy that includes autologous hsct this indication is approved under accelerated approval based on overall response rate see clinical studies 14 6 opdivo is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck scchn with disease progression on or after platinum based therapy opdivo is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who this indication is approved under accelerated approval based on tumor response rate and duration of response see clinical studies 14 8 opdivo as a single agent or in combination with ipilimumab is indicated for the treatment of adult and pediatric patients 12 years and older with microsatellite instability high msi h or mismatch repair deficient dmmr metastatic colorectal cancer crc that has progressed following treatment with a fluoropyrimidine oxaliplatin and irinotecan this indication is approved under accelerated approval based on overall response rate and duration of response see clinical studies 14 9 opdivo is indicated for the treatment of patients with hepatocellular carcinoma hcc who have been previously treated with sorafenib this indication is approved under accelerated approval based on tumor response rate and durability of response see clinical studies 14 1";
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
    bl:provided_by <https://w3id.org/um/NeuroDKG>;
    bl:relation schema:TreatmentIndication .
  
  <https://identifiers.org/drugbank:DB09035> bl:category bl:Drug .
}

sub:provenance {
  sub:assertion ns1:wasAttributedTo orcid:0000-0002-1468-3557 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
    npx:hasSignature "FH3USB3QOaerGJmhx4XzZ2b28e0UBIIXQ0gXfqpfTG3WyAA85sGaiH6DahAGZiyUXgSjpOw6u6UZNYcOBzfuxftlF1oTZ5Kyc+ZPHjGTO0him3fJoQU//DIVmZQ+Pw0BtaWIf3SETNcMJFM1FF5IrBIrhOdhi/LgQI2gwQQWTQw=";
    npx:hasSignatureTarget this: .
  
  this: dcterms:created "2021-07-03T15:33:18.413+02:00"^^xsd:dateTime;
    dcterms:creator orcid:0000-0002-1468-3557;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs> .
}